Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
GH Research PLC (NASDAQ:GHRS) is one of the
10 Stocks That Have the Potential to Rise 1000%.
On May 19, 2026, H.C. Wainwright lowered the firm’s price target on GH Research PLC (NASDAQ:GHRS) to $65 from $70 and maintained a Buy rating on the shares. H.C. Wainwright cited share count dilution from the company’s April offering for the target cut.
On May 15, 2026, Cantor Fitzgerald raised the firm’s price target on GH Research PLC (NASDAQ:GHRS) to $35 from $25 and maintained an Overweight rating on the shares. Cantor Fitzgerald said GH Research operates in a large and expanding psychedelic therapy market with significant unmet mental health needs. The firm said long-term peak sales across related treatments could reach roughly $50B, supporting a constructive demand backdrop despite uncertainty around competitive dynamics.
A day earlier, GH Research PLC (NASDAQ:GHRS) reported Q1 EPS of (31c), compared to the consensus estimate of (26c). CEO Velichka Valcheva said the quarter marked progress toward the company’s global GH001 Phase 3 pivotal program.
GH Research PLC (NASDAQ:GHRS) is a clinical-stage biopharmaceutical company developing treatments for depression in the United States.
While we acknowledge the potential of GHRS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
